Continuous Hemodiafiltration with an AN69ST Hemofilter (AN69ST-CHDF) as FGF-23-Lowering Therapy.
BACKGROUND
Recent studies have shown that fibroblast growth factor-23 (FGF-23) is elevated not only in chronic kidney disease (CKD), but also in acute illnesses such as acute kidney injury, septic shock, and acute heart failure. FGF-23 would be not only a simple biomarker but also a direct toxic factor in acute illness. Therefore, lowering circulating FGF-23 levels in clinical practice would be an exciting and valuable interventional strategy. Continuous hemodiafiltration (CHDF) is often performed for the treatment of the aforementioned acute illnesses. We have previously reported that an acrylonitrile-co-methallyl sulfonate surface-treated (AN69ST) membrane has a greater capacity for in vitro FGF-23 adsorption than polysulfone and polymethyl methacrylate membranes. However, reports related to the influence of AN69ST-CHDF on serum FGF-23 levels in acute illness are lacking. In this study, we investigated the effect of AN69ST-CHDF on circulating FGF-23 concentrations in clinical practice.


METHODS
Subjects comprised six inpatients who underwent AN69ST-CHDF for an acute illness. Blood samples for the measurement of serum FGF-23 were collected at 0, 3, and 12 hours post-treatment. Blood samples were also drawn from the extracorporeal circuit at the inlet and outlet of the hemofilter 3 hours after CHDF initiation, in order to calculate the clearance of serum FGF-23.


RESULTS
Three and 12 hours after the start of AN69ST-CHDF, circulating FGF-23 levels decreased from baseline values with a marginal statistical significance (p = 0.0625 and 0.0938, respectively). An FGF-23 clearance of 27.5 [interquartile range: 19.4 - 29.2] mL/minute 3 hours after the initiation of AN69ST-CHDF was achieved.


CONCLUSIONS
Our results suggest that AN69ST-CHDF can be a novel FGF-23 lowering therapy for acute illnesses requiring acute blood purification.
Masafumi
M
Yamato
Yusuke
Y
Minematsu
Yuta
Y
Ikemiya
Junichi
J
Shibata
Junya
J
Fujii
Takumi
T
Minato
Sachie
S
Miyagawa
Kaori
K
Takaori
Yoko
Y
Tomiyama
Ikue
I
Nagayama
Akira
A
Wada
Takahito
T
Ito
Hirotsugu
H
Iwatani
D000180:Acrylic Resins / Q000737:chemistry*; D000181:Acrylonitrile / Q000031:analogs & derivatives* / Q000737:chemistry; D000208:Acute Disease / Q000628:therapy*; D000327:Adsorption; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015536:Down-Regulation; D004867:Equipment Design; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D017583:Hemodiafiltration / Q000295:instrumentation*; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011485:Protein Binding; D013499:Surface Properties; D013997:Time Factors; D016896:Treatment Outcome
D000180:Acrylic Resins; D015415:Biomarkers; C000717427:FGF23 protein, human; D008567:Membranes, Artificial; C016892:AN-69; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000181:Acrylonitrile